These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21678719)

  • 1. Adverse reactions: know the risks.
    Shepherd M
    Nurs Times; 2011 Apr 5-11; 107(13):20. PubMed ID: 21678719
    [No Abstract]   [Full Text] [Related]  

  • 2. Nurses must report adverse drug reactions.
    Griffith R
    Br J Nurs; 2013 Apr 25-May 8; 22(8):484-5. PubMed ID: 23905231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visual impairment owing to adverse drug reaction: incidence and routine monitoring in the United kingdom.
    Cumberland PM; Russell-Eggitt I; Rahi JS
    Ophthalmology; 2014 May; 121(5):1152-4. PubMed ID: 24612978
    [No Abstract]   [Full Text] [Related]  

  • 4. Reporting suspected adverse reactions.
    Diesel G; Anderson N; Ursich E
    Vet Rec; 2019 May; 184(20):623. PubMed ID: 31097563
    [No Abstract]   [Full Text] [Related]  

  • 5. Suspected adverse reactions, 2003.
    Dyer E; Mulugeta R; Evans C; Tait A
    Vet Rec; 2004 Jun; 154(26):806-8. PubMed ID: 15260440
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of hospital episodes with 'drug-induced' disorders and spontaneously reported adverse drug reactions.
    Barrow P; Waller P; Wise L
    Br J Clin Pharmacol; 2006 Feb; 61(2):233-7. PubMed ID: 16433879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug makers' adverse event reports are often incomplete, US report finds.
    McCarthy M
    BMJ; 2015 Feb; 350():h651. PubMed ID: 25652561
    [No Abstract]   [Full Text] [Related]  

  • 8. Adverse drug reactions in hospital and in the community.
    D'Arcy PF
    Adverse Drug React Toxicol Rev; 1997 Jun; 16(2):95-101. PubMed ID: 9359931
    [No Abstract]   [Full Text] [Related]  

  • 9. [Adverse drug reactions reporting is helping "non substituable" prescription!].
    Jacquot J; Bagheri H; Montastruc JL
    Therapie; 2014; 69(3):259-61. PubMed ID: 24927508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical methods for the analysis of adverse event data.
    Kieser M
    Pharm Stat; 2016 Jul; 15(4):290-1. PubMed ID: 27324410
    [No Abstract]   [Full Text] [Related]  

  • 11. Comment on: "Adverse drug reaction reporting by patients: an overview of fifty countries".
    Ahmad SR
    Drug Saf; 2015 Jan; 38(1):109-10. PubMed ID: 25414075
    [No Abstract]   [Full Text] [Related]  

  • 12. Authors' reply to Ahmad SR: "Adverse drug reaction reporting by patients: an overview of fifty countries".
    Margraff F; Bertram D
    Drug Saf; 2015 Jan; 38(1):111. PubMed ID: 25414076
    [No Abstract]   [Full Text] [Related]  

  • 13. What Is the Plural of a 'Yellow' Anecdote?
    Evans SJ
    Drug Saf; 2016 Jan; 39(1):1-3. PubMed ID: 26597283
    [No Abstract]   [Full Text] [Related]  

  • 14. What can data mining teach us about triptan safety that we don't already know?
    Loder E; Burch R
    Cephalalgia; 2014 Jan; 34(1):3-4. PubMed ID: 23918835
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety surveillance of longitudinal databases: further methodological considerations.
    Schuemie MJ
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):670-2; author reply 673-5. PubMed ID: 22678687
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety surveillance of longitudinal databases: methodological considerations.
    Norén GN; Hopstadius J; Bate A; Edwards IR
    Pharmacoepidemiol Drug Saf; 2011 Jul; 20(7):714-7. PubMed ID: 21638520
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial: harmonization in pharmacoepidemiological studies: (twi)light at the end of the tunnel?
    Mangoni AA
    Curr Clin Pharmacol; 2014 May; 9(2):91-2. PubMed ID: 24702185
    [No Abstract]   [Full Text] [Related]  

  • 18. Is the yellow card road going in the right direction?
    Evans SJ
    Drug Saf; 2015 Jun; 38(6):517-8. PubMed ID: 25948507
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study.
    Martin RM; Kapoor KV; Wilton LV; Mann RD
    BMJ; 1998 Jul; 317(7151):119-20. PubMed ID: 9657787
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.